A Phase II Study Examining the Feasibility of Long Term and Low Dose Oral Capecitabine (Xeloda) in Newly Diagnosed Head and Neck Squamous Cell Carcinoma After Surgery, Radiation and/or Chemotherapy.

Trial Profile

A Phase II Study Examining the Feasibility of Long Term and Low Dose Oral Capecitabine (Xeloda) in Newly Diagnosed Head and Neck Squamous Cell Carcinoma After Surgery, Radiation and/or Chemotherapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Mar 2012

At a glance

  • Drugs Capecitabine (Primary)
  • Indications Head and neck cancer; Various toxicities
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Mar 2012 Actual end date (Feb 2011) added as reported by ClinicalTrials.gov.
    • 13 Mar 2012 Actual patient number is 35 and additional lead trial centre identified according to ClinicalTrials.gov.
    • 13 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top